CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 99 enrolled
Drug / intervention
PegIntron (peginterferon alfa-2b; SCH 54031) +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00728494
NCT00728494N/ACompleted
CompareCT.gov

Evaluation of Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron / Rebetol in Conjunction With a Patient Assistance Program - Non Interventional Observational Study.

Merck Sharp & Dohme LLC·observational·Posted Aug 5, 2008·Updated Jul 28, 2015

In Brief

An observational study evaluating PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908), and 1 other intervention for Hepatitis C, Chronic and Hepatitis C. Completed, enrolled 99 participants.

Detailed Summary

Enrolled patients will be recruited to two parallel groups during therapy for Hepatitis C. Patients in the first one will receive a patient assistance program, and patients in the second group will not. All patients will receive PegIntron and Rebetol according to label.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic, Hepatitis C
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 5, 2008
Enrollment StartOct 1, 2005
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.9 years ago

Interventions

PegIntron (peginterferon alfa-2b; SCH 54031)biological

Peginterferon alfa-2b will be administered according to the product's labeling.

Rebetol (ribavirin; SCH 18908)drug

Ribavirin will be administered according to the product's labeling.

Patient Assistance Programbehavioral

The patient assistance program includes the following: * Training by physicians or specialized nurses. * Informational materials based on the "To beat HCV" program. * Management of specific side effects.